REGENXBIO Inc.
Financials
Valuation Metrics
REGENXBIO Inc.'s Market Cap is $473M. At end of 2025 it was $745M. Ranked #2757 of 3,118 in US market (top 88%), #1207 of 1,474 on NASDAQ (top 82%), #218 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $473M | US#2,757/3,118 Sec#218/265 |
| Revenue | $174M | US#2,574/3,118 Sec#113/265 |
| Net Income | $-196M | US—/3,118 Sec—/265 |
| Total Assets | $387M | US#2,847/3,118 Sec#189/265 |
| Net Assets | $72M | US#2,826/3,118 Sec#217/265 |
| Employees | 371 | US#2,349/3,118 Sec#98/265 |
| Value | ||
| P/B | 6.60x | US#2,412/3,118 Sec#165/265 |
| P/S | 2.71x | US#1,593/3,118 Sec#44/265 |
| FCF Yield | -52.75% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | -50.81% | US#2,986/3,118 Sec#216/265 |
| Op. Margin | -94.08% | US#2,706/3,118 Sec#123/265 |
| Revenue Growth | 12.00% | US#1,089/3,118 Sec#88/265 |
| Financial Health | ||
| Debt Ratio | 438.73% | US#2,304/3,118 Sec#221/265 |
| Total Debt | $69M | US#2,528/3,118 Sec#140/265 |
| FCF | $-250M | US#2,818/3,118 Sec#227/265 |
| Cash | $36M | US#2,696/3,118 Sec#239/265 |
| Current Ratio | 2.86x | US#823/3,118 Sec#196/265 |
| Performance | ||
| 1Y Return | -43.85% | US#2,793/3,118 Sec#227/265 |
| 1M Return | -3.50% | US#2,141/3,118 Sec#148/265 |
| From 52W High | -55.71% | US#2,745/3,118 Sec#213/265 |
| 1Y MDD | -64.64% | US#2,830/3,118 Sec#219/265 |
| Trading | ||
| Volume | 877,990 shares | US#1,622/3,118 Sec#156/265 |
| Trading Value | $6M | US#2,526/3,118 Sec#198/265 |
| Per Share | ||
| EPS | $-2.98 | US—/3,118 Sec—/265 |
| BPS | $1.09 | US#2,678/3,118 Sec#200/265 |
Company Info
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.